Australia, July 29 -- CG Oncology Inc., owns the trademark (2508791) for 'CG CG ONCOLOGY ONCOLYTIC IMMUNOTHERAPY' and 'RING,INCOMPLETE & ENDLESS-BELT,NOTCHED-SIDE,DIVIDED FORM LTRS CG,INTERLOCKING' till Dec. 20, 2034.
Status: registered:
Registered/protected
Classes: 5 [Pharmaceutical products for the treatment of cancer; pharmaceutical preparations and biological preparations for the treatment of cancer and immunological disorders; Biopharmaceuticals for the treatment of cancer, namely, antibodies, non-antibody proteins, blood and blood components, stem cells, hormones, blood factors, tumor necrosis factors; Chemical preparations for medical or pharmaceutical purposes, namely, for cancer treatment, oncology and immunotherapy for auto immune diseases; Pharmaceutical products, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing] and 42 [Pharmaceutical research and development; Providing medical and scientific research information in the fields of oncology, autoimmune disorders, immunotherapy, immunotherapeutics, biotechnology, biopharmaceuticals, pharmaceuticals, therapies, diseases, and disorders]
Type of Mark: Figurative
Date of Acceptance: Feb. 17
Registration Advertised: July 28
For further details contact Ashurst Australia.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2508791.
Disclaimer: Curated by HT Syndication.
